Abstract
BACKGROUND: The use of energy-based devices (EBDs) for aesthetic and dermatological conditions is increasing, but data on efficacy and safety in autoimmune connective tissue disease (CTD) patients remain limited. OBJECTIVES: This study assesses EBD real-world treatment outcomes in Korean patients with lupus erythematosus (LE) and dermatomyositis (DM). METHODS: A retrospective, uncontrolled study was conducted on 26 CTD patients (LE: 20, DM: 6) treated at Hanyang University Seoul Hospital (2015-2023). Various laser modalities, including pulsed-dye laser (PDL), intense pulsed light (IPL), long-pulse Nd:YAG (LPNY), Q-switched Nd:YAG (QSNY), and ablative fractional laser (AFL), were analyzed. Two independent dermatologists evaluated treatment outcomes using a 5-point modified Investigator's Global Assessment (IGA) scale. RESULTS: Patients showed significant improvement in erythema, dyspigmentation, and overall skin morphology. Some LE patients also exhibited enhanced follicular activity. Treatments were well-tolerated, with only transient side effects reported, and no long-term complications or disease reactivation occurred. CONCLUSIONS: EBD treatments may provide cosmetic improvement in selected LE and DM patients and are generally safe. Larger controlled studies are needed to confirm efficacy and establish optimal protocols.